

**REMARKS**

In the Office Action, the Examiner noted that claims 1-15 are pending and that claims 1-15 are rejected.

Applicants respectfully disagree. Nonetheless to advance prosecution of select embodiments of the invention, applicants provide the amendments hereinabove. In doing so, applicants do not acquiesce to the official position and expressly reserve the right to continue prosecution otherwise.

By this amendment, claims 2 and 3 have been amended; claims 4-15 have been withdrawn; claim 1 remains as originally filed; and claims 16 and 17 are new. Thus claims 1-3 and 16-17 are pending in the application.

**Rejection under 35 USC 112, First Paragraph.**

The Examiner alleges that the Claims fail to comply with the enablement requirement because the claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to make or use the invention.

The Examiner further asserts that the claims are broad with respect to diseases being treated especially in light of the absence of a common biochemical mechanism underlying the claimed disorders. Amended claim 3 is limited to a method of treating Alzheimer's Disease. At the time of the present invention, it was generally believed by the scientific community that a causal relationship existed between Alzheimer's Disease and the accumulation of toxic amyloid material resulting from the interaction of beta-secretase with a precursor protein. In an article entitled "The potential of BACE inhibitors for Alzheimer's therapy" the authors (H. Potter and D. Dressler) *predict* that a cure will be found for Alzheimer's Disease through the modulation of the enzyme beta-secretase (Nature Biotechnology, 18, p. 125, February, 2000).

Applicant submits that the scope of protection sought under amended claim 3 and new claims 16 and 17 is commensurate with the scope of enablement that pertains to same as provided by the disclosure to one of ordinary skill in the art. For example, the  $IC_{50}$  value of  $49 \times 10^{-9}$  M demonstrates that the compound of formula I is a potent inhibitor of  $\beta$ -secretase. Dosage and formulation given in the specification allows one skilled in the art to select appropriate conditions to use the invention without undue experimentation. An inventor need not explain every detail, since he is speaking to those skilled in the art. Withdrawal of the rejection is respectfully requested.


In the Office Action mailed on May 16, 2003 the Examiner has stated that the compound of formula I is novel and unobvious over the prior art. Applicant respectfully requests withdrawal of the rejection of claim 1 drawn to the compound of formula I and amended claim 2 to a pharmaceutical formulation based upon the compound of formula I.

For the reasons advanced above, applicant respectfully submits that this application is in condition for allowance and that action is earnestly solicited.

The Commissioner is hereby authorized to charge any appropriate fees required for this Amendment to Deposit Account No. 16-1445.

Date: August 25, 2005

Respectfully submitted,

  
Stuart P. Suskind  
Registration No. 40,192